Products
We provide a portfolio of primary and patient-derived cells, organoids, ECM-based 3D platforms, and ready-to-use systems designed for translational and preclinical research.
- ADMET: Organ-specific primary cells (liver, kidney, intestine, lung, skin, brain, endothelial) and tissue-derived products support predictive PK, metabolism, and toxicity studies, including co-culture and multi-cellular models.
- Oncology: Patient-derived tumor cells, cancer-associated fibroblasts, immune components, and ECM hydrogels enable translational studies of tumor heterogeneity, stromal interactions, and therapeutic response.
- Immunology: Patient-derived immune cells, integrated with tumor or stromal products, allow functional assays such as cytotoxicity, cytokine profiling, and checkpoint inhibitor testing.
- Metabolic Diseases and Fibrosis: Primary and patient-derived cells and ECM preparations are available to support research in type 2 diabetes, NASH and liver fibrosis, cardiac fibrosis, and pulmonary fibrosis. Disease-relevant cell populations and matched ECM can be supplied to enable modeling of fibrotic remodeling, metabolic dysfunction, and inflammatory signaling.
All products are designed for scalability, reproducibility, and can be customized to match specific pipeline needs.
We offer a variety of 3D models, including ECM-embedded spheroids, patient-derived tumor cultures, co-culture systems that combine epithelial, stromal, and immune cells, and hydrogel-based scaffolds derived from human ECM. All models are compatible with high-content imaging, drug screening, long-term culture, and mechanistic studies. Customization of these models is available to meet specific research questions or disease-specific requirements.
Customization
Yes, Preci can provide non-catalog materials. This includes rare tissue types, specific donor characteristics, custom subcellular fractions, and tailored ECM preparations.
Yes. We support the development of customized in vitro workflows, including mechanistic studies, drug screening strategies, biomarker validation, and functional readouts relevant to oncology, metabolism, or inflammation.
Yes. We provide outsourced preclinical services, including 3D model development, compound testing, feasibility studies, and proof-of-concept validation. Projects can be structured as short pilot studies or milestone-based collaborations.
Quality and Compliance
Validation data may include Certificates of Analysis, viability and functional assays, protein quantification for ECM products, histological confirmation for tissues, batch-to-batch comparison data, and sterility or mycoplasma testing. Additional validation can be discussed based on project requirements.
Yes. Preci operates under current approvals from independent Ethics Committees (EC) or Institutional Review Boards (IRB) covering the collection, storage, use, and disposal of human biosamples and associated data.
Procedures comply with applicable Ukrainian and EU regulatory frameworks. Documentation can be provided upon request.
All materials are supplied for research use only.
Support
Yes, we provide technical support throughout your project, including guidance on experimental design, product handling, troubleshooting, and protocol recommendations.
Sample availability depends on product type and batch status. Feasibility can be assessed upon request.
Preci uses either ADR-compliant land transport or World Courrier shipments for the European transport of HBS. Preci has validated the compliance of Ukrainian World Courier’s office for organization of its HBS deliveries according to ADR and ICAO regulations. Temperature-controlled shipping options are available where required.
Delivery times depend on the product type, batch availability, and shipping destination. Our team will provide estimated timelines at the time of order confirmation.